Ian S Maze, PhD
- ASSOCIATE PROFESSOR | Neuroscience
- ASSOCIATE PROFESSOR | Pharmacological Sciences
Research Topics:
Addiction, Behavior, Chromatin, Depression, Drug Design and Discovery, Gene Expressions, Molecular Biology, Neuroscience
Ian S. Maze, Ph.D., is a neurobiologist with extensive training in the molecular biology and chromatin biochemistry of histone regulation in the mammalian central nervous system. His multidisciplinary and integrative research involves the use of biochemical, biophysical, physiological and behavioral analyses to explore the molecular underpinnings of neurodevelopmental and adult cognitive and psychiatric disorders. Dr. Maze is actively investigating the brains of rodents and postmortem humans, as well as human iPSC-derived neurons, to uncover chromatin-based mechanisms of neurological disease.
Multi-Disciplinary Training Areas
Development, Regeneration, and Stem Cells [DRS], Neuroscience [NEU], Pharmacology and Therapeutics Discovery [PTD]Education
BS, The Ohio State University
PhD, Mount Sinai School of Medicine
Postdoctoral Fellowship, The Rockefeller University
-
2019
Dr. Harold and Golden Laport Basic Research Award -
2019
Winner of Presidential Early Career Award for Scientists and Engineers (PECASE) -
2015
ACNP Travel Award -
2015
MQ: Transforming Mental Health Research Fellowship Award -
2014
NARSAD Young Investigator Award -
2011
Terry A. Krulwich Dissertation Award, Mount Sinai School of Medicine
The Maze laboratory is focused on understanding the role of chromatin dynamics, nucleosomal turnover and histone variant exchange in the central nervous system during periods of transcriptional, synaptic and behavioral plasticity. Extended emphasis is placed on investigating the functions of novel neuronal specific/enriched histone modifications and ‘reader’ proteins, as well as their role in developmental neurological disorders (e.g. Down syndrome) and adult psychiatric illness. Current projects include the utilization of chromatin biochemical techniques, genome-wide sequencing analyses and viral vector-based gene modification systems to investigate novel histone-based mechanisms of monoaminergic dysfunction in major depressive disorder. Search PubMed for publications
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Maze did not report having any of the following types of financial relationships with industry during 2020 and/or 2021: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.